Additionally, the KEYNOTE-091 phase III adjuvant immunotherapy study (35) demonstrated that pembrolizumab significantly improved DFS compared with placebo in completely resected stage IB–IIIA NSCLC, regardless of PD-L1 expression levels (HR, 0.76, P = 0.0014). The gene discussed is CD274; the disease is non-small cell lung carcinoma.